SRRK
|
Scholar Rock Holding Corporation
|
0.05%
|
US
|
NASDAQ
|
SIGA
|
SIGA Technologies Inc.
|
0.05%
|
US
|
NASDAQ
|
SGMO
|
Sangamo BioSciences, Inc.
|
0.05%
|
US
|
NASDAQ
|
PTGX
|
Protagonist Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
PSTX
|
Poseida Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
NRIX
|
Nurix Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
MRSN
|
Mersana Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
KNSA
|
Kiniksa Pharmaceuticals, Ltd.
|
0.05%
|
US
|
NASDAQ
|
IGMS
|
IGM Biosciences, Inc.
|
0.05%
|
US
|
NASDAQ
|
HLVX
|
HilleVax, Inc.
|
0.05%
|
US
|
NASDAQ
|
FULC
|
Fulcrum Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
FATE
|
Fate Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
EWTX
|
Edgewise Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
ETNB
|
89bio, Inc.
|
0.05%
|
US
|
NASDAQ
|
ESPR
|
Esperion Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
EDIT
|
Editas Medicine, Inc.
|
0.05%
|
US
|
NASDAQ
|
DSGN
|
Design Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|
CGEM
|
Cullinan Management, Inc.
|
0.05%
|
US
|
NASDAQ
|
CBAY
|
CymaBay Therapeutics Inc.
|
0.05%
|
US
|
NASDAQ
|
CARA
|
Cara Therapeutics, Inc.
|
0.05%
|
US
|
NASDAQ
|